STATISTICS IN MEDICINE, VOL. 6, 973–974 (1987)

AUTHOR INDEX

Abel, U., 127
Andersen, B., 3
Anthony, H. M., 761
Arena, V. C., 71
Azen, S. P., 689

Bailey, K. R., 351
Bateman, D. N., 863
Bayer, T., 939
Bean, J. A., 61
Begg, C. B., 411
Bell, C. M. J., 901
Bergmann, E., 823
Bergmann, K., 823
Berrier, J., 315, 733
Bléry, C., 813
Brandenhoff, P., 3
Brown Jun., B. Wm., 483
Buring, J. E., 397
Busse. H., 823
Buyse, M., 565

Canner, P. L., 255
Chakraborty, R., 629
Chalmers, T. C., 315, 733
Charny, M., 869
Charpak, Y., 813
Chassagne, D., 785
Chastang, C., 795, 813
Chen, R., 517
Chuang, C., 583
Clayton, D., 449, 469
Coates, A., 667
Coleman, D. A., 901
Collett, D., 853
Collins, R., 245
Connett, J. E., 53
Cook, T., 599
Crichton, N. J., 805, 945
Curnow, R. N., 113

D'Agostino, R., 79
de Boo, Th. M., 843
DeMets, D. L., 341, 753
de Stavola, B., 881
Divine, G. W., 591
Dixon, D. O., 591
Donald, A., 43, 491
Donner, A., 43, 441, 491, 647
Dorey, F. J., 679

Elashoff, R. M., 31
Eliasziw, M., 441, 647
Ellenberg, S., 217
Emerson, J. D., 101
Emerson, P. A., 805
Emerson, S., 361

Fleming, T. R., 361
Forbes, J., 667
Franti, C. E., 961
Friedman, M. A., 307
Fryer, J. G., 945
Furberg, C. D., 295

Gebski, V., 667
Gelber, R. D., 371
Godwin, J., 245
Goldhirsch, A., 371
Gray, R., 137, 245
Green, S. J., 361
Greenhouse, J. B., 167
Greenland, S., 193, 701
Griffiths, K., 425
Guttler, F., 3

Halpern, J., 483
Hanis, C. L., 629
Hebert, P. R., 397
Hedges, L. V., 381
Heeren, T., 79
Hempenius, A. L., 501
Hennekens, C. H., 397
Hilden, J., 745
Hsieh, F. Y., 577

Jais, J. P., 795
Jones, B., 555, 911

Karlberg, J., 185
Kass, R. E., 167
Keiding, N., 939
Kemp, K. W., 425
Kenward, M. G., 555, 911
Korn, E. L., 679
Krailo, M. D., 119
Kramar, A., 785
Kraus, J. F., 961
Kurashina, S., 709

Lawrence, C. J., 159
Levin, H., 315, 733
Lewis, P. A., 869
Light, R. J., 221
Linnet, K., 147
Lubsen, J., 927
Lye, M. S., 853

Martin, C. J., 613
McHugh, R. B., 53
McNeil, D., 667
Meier, P., 329
Morgan, T. M., 31, 295
Mulder, P. G. H., 501

Nagalingam, R., 315, 733
Neff, N., 197
Niland, J. C., 689
Nix, A. B. J., 425
Norton, L., 333

Olschewski, M., 773

Palta, M., 599
Pejovic, M. H., 785
Peto, R., 233, 245
Plantinga, A. D., 843

Raphael, J. C., 795
Rawlins, M. D., 863
Reitman, D., 315, 733
Rockette, H. E., 71
Rowlands, R. J., 425
Ryan, L. M., 565

Sacks, H. S., 315, 733
Schifflers, E., 449, 469
Schmoor, C., 773
Schumacher, M., 773
Shewmon, D. A., 535
Shih, W. J., 91
Simes, R. J., 11
Simon, R., 217, 389
Simpson, J. M., 863
Smith, J. A., 53
Snapinn, S. M., 657
Southall, D. P., 159
Spicer, C. C., 159, 945
Sposto, R., 119
Stitt, L. W., 885

Tango, T., 709
The French Cooperative Group on Plasma Exchange in Guillain–Barré Syndrome, 795
Thomas, D., 689
Tijssen, J. G. P., 927
Tritchler, D., 101
Tsay, R. S., 167
van Druten, J. A. M., 843
van Es, G.-A., 927
Wallenstein, S., 197
Walter, S. D., 885
Wastell, D. G., 137
Watt-Boolsen, S., 939
Wiggins, A. D., 961
Wilson, D. W., 425
Wiltse, C. G., 61
Wittes, R. E., 269
Woolson, R. E., 61
Wulff, H. R., 3
Yusuf, S., 217, 281

STATISTICS IN MEDICINE, VOL. 6, 975–981 (1987)

SUBJECT INDEX

((L) indicates subject discussed in Letter to the Editors)

Abdominal pain, 945
Abortion, 197
Adjusted rates, 61, 193
Adjustment for covariates, 31, 255, 911
Adverse drug reactions (ADR), 863
Adverse effects, treatment, 745, 863
Age–cohort model, 449
Age–period model, 449
Age–period–cohort model, 449, 469, 709
Age standardized rates, 61, 449, 469
Aggregation, data, 11, 217–410, 565, 733, 823
Algorithm, EM, 91
Allocation, treatment, 119, 127, 241, 577
Alternative medicine, 761
Anaemia, 689
Analgesics, 555, 657
Analysis of covariance, 911
Analysis of variance, repeated measures, 441, 599, 647, 911
Angle chart, quality control (quangle), 425
Antimicrobial drugs, 91
ARMA model, 167
Ascertainment bias, 961
Aspirin, 255, 351
Aspirin myocardial infarction study (AMIS), 255
Assay, direct, 583
Attributable fraction, 701
Autocorrelation, 159, 167, 689

Balance of treatments in clinical trials, 119, 127, 241, 577
Baseline observation, clinical trials, 911
Bayes model, independence, 805, 945
Bayes's theorem, 535, 805
Beta-binomial distribution, 491
Beta-blocker heart attack trial (BHAT), 753
Beta-blockers, 233, 281, 305, 315, 733
Bias, ascertainment, 961
Bias, lead-time, 885
Bias, length, 885
Bias, meta-analysis, 11, 217–410, 565, 733
Bias, publication, 11, 221, 229, 295, 315, 327, 333, 361, 733
Bias, review, diagnostic test, 411
Bias, selection, 127, 251, 315, 389
Bias, verification, 411
Bile acids, serum, 147
Binary response crossover trials, 555
Binomial distribution, negative, 823
Binomial variation, extra, 491
Birth defects, surveillance of, 517
Body temperature, 167
Bonferroni method, 591
Book Reviews
  D. J. Hand and B. S. Everitt (Ed), *The Statistical Consultant in Action*, 875
  D. Ingram and B. Bloch, *Mathematical Methods in Medicine, Part II, Applications in Clinical Research*, 211
  W. Lehmacher and A. Hormann, *Statistik Software: 3 Konferenz uber die Wissenochaftliche Anwendung von Statistik-Software*, 212
  O. S. Miettinen, *Theoretical Epidemiology*, 209
  Symposium on Methodology and Quality Assurance in Cancer Clinical Trials, 213
Bowel disease, 785
Box–Jenkins model, 159
Brain death, 535

Cancer, 217, 389
  bladder, 449
  breast, 233, 245, 251, 269, 287, 329, 333, 337, 371, 389, 469, 667, 881, 885, 939
  cervix, 785
  chemotherapy, 11, 245, 251, 265, 269, 277, 287, 307, 329, 333, 337, 389, 667
  clinical trials, 11, 31
  colon, 307, 313
  epidemiology, 449, 469
  face, 881
  Hodgkin's disease, 517
  incidence, 449, 469
  liver, 307
  lung, 31, 449
  lymphoma, 307
  mortality, 449, 469, 881
  myeloma, 11, 517
  ovarian, 11, 307
  radiotherapy, 785
  rectal, 565
  recurrence, 245, 251
  screening, 885
  stomach, 307
  uterus, 881
Cardiff health survey, 869

Cardiovascular disease, 217, 233, 295, 501
Caries, 823
Carryover effects, crossover trials, 555, 911
Case-control study, 53, 701
  power, 53
  size, 53
  type I error, 53
Cause-deleted life tables, 527(L)
Cause-specific mortality, 71
Censored observations, 31, 119, 483, 501, 565, 583, 591, 667, 679, 773, 785, 795, 927, 939
Chemotherapy, cancer, 11, 245, 251, 265, 269, 277, 287, 307, 329, 333, 337, 389, 667
Chemotherapy, mass, 853
Chest disease, 805, 813
Cholesterol, 241, 501
Circadian rhythm, 167
Cirrhosis, 709
Classification, 137, 945
Clemmesen's hook, 469
Clinical chemistry, 147, 411, 425
Clinical decision-making, 101, 745, 753, 805
Clinical trials,
  adverse treatment effects, 745
  allocation of treatment, 119, 127, 241, 577
  analgesics, 657
  balance of treatments, 119, 127, 241, 577
  baseline observation, 911
  cancer, 11, 31, 939
  cardiovascular disease, 295
  cholesterol, 241
  combination of, 11, 217–410, 565, 733
  community intervention, 43
  complementary medicine, 761
  computer database of, 11
  crossover, 555, 911
  data monitoring, 753
  decision rules, 753
  design, 43, 119, 127, 577, 667, 761, 773, 813
  early termination, 361, 369, 667, 753, 927
  efficacy of treatment, 101, 657, 761
  errors in covariates, 31
  factorial designs, 773
  group sequential, 361, 369, 753, 927
  imbalance in treatment allocation, 119, 127, 241, 577
  interaction, qualitative, 329, 351, 359, 371, 387
  interaction, quantitative, 329, 359, 371, 387
  interaction, stratum-covariate, 221, 233, 371, 381, 773
  interim analysis, 361, 369, 753, 927, 939
  meta-analysis, 11, 217–410, 565, 733
  multistate model, 795
  myocardial infarction, 351
  overview of, 11, 217–410, 565, 733
  patient selection, 113
  placebo effect, 113
Clinical trials—*contd*
  pooling, 11, 217–410, 565, 733
  power, 119, 577, 773, 927
  pragmatic, 101, 389
  randomization, 43, 119, 127, 229, 233, 241, 251
  register of, 11, 327
  regression to the mean, 113, 727(L), 728(L)
  repeated significance tests, 753
  replacement randomization, 127
  sequential analysis, 361, 369, 753
  size, 119, 577, 667
  stopping rules, 361, 369, 667, 753, 927
  stratum-covariate interaction, 221, 223, 371, 381, 773
  three-period crossover, 555
  treatment allocation, 119, 127, 241, 577
  treatment balance, 119, 127, 241, 577
Workshop on Methodologic Issues in Overviews, 217–410
Cluster analysis, 137
Cluster, disease, 197, 491
Cluster randomization, 43
Cluster, space–time, 197
Cohort analysis, 449, 469, 709
Cohort study, 689, 901
Coma, 535
Combination preparations, 657
Combining clinical trials, 11, 217–410, 565, 733
Combining probabilities, 265, 341, 381, 387
Combining proportions, 565
Committee on Safety of Medicines (CSM), 863
Community intervention clinical trials, 43
Comparison of diagnostic tests, 147
Comparison of means, 79
Comparison of sensitivities, 147
Comparisons, multiple, 71, 591
Competing risks model, 785
Complementary medicine, 761
Compound symmetry, 911
Computer database of clinical trials, 11
Concordance ratio, 961
Confidence interval, survival probability, 679
Confirmatory analyses, 939
Congenital rubella syndrome, 843
Contingency tables, 491
  missing data, 91
  square, 91
Coronary drug project aspirin study (CDPA), 255
Correlation coefficient, 3, 441
  familial, 629
  intraclass, 43, 647
  intracluster, 491
Cosinor analysis, 167
Cost function, 647
Covariance, analysis of, 911
Covariate adjustment, 31, 255, 911

Covariate-stratum interaction, 221, 233, 371, 381, 773
Cos proportional hazards model, 31, 501, 591, 773
Crossover clinical trials, 555, 911
Cumulative sum (CUSUM) technique, 425, 517
Cure rate model, 483
Curtailment, stochastic, 667, 753, 927
Curvature components, age–period–cohort model, 709
Cusum techniques, 425, 517
Cytology screening, 885

Data aggregation, 11, 217–410, 565, 733, 823
Data monitoring, clinical trials, 753
Database of clinical trials, computer, 11
Death, declaration of, 535
Decision aids, clinical, 805, 945
Decision rules, 753
Decision theory, 101, 745
Dendrogram, 137
Dental caries, 823
Dentistry, preventive, 823
Design of clinical trials, 43, 119, 127, 577, 667, 761, 773, 813
Design of questionnaires, 613
Detectable preclinical phase (DPCP), 885
Diabetes, 709
Diagnosis, 529(L), 530(L), 805, 945
Diagnostic tests, 147, 411, 813
Diagnostic tests, power, 147
  sample size, 147
Dietz, Mollineaux and Thomas (DMT) model, 853
Discordance ratio, 961
Discriminant analysis, 137, 159
Discrimination limits, 147
Disease cluster, 197
Disease monitoring, 197
Disease-specific mortality, 71, 233
Distribution, beta-binomial, 491
  exponential, 501, 565
  negative binomial, 823
  piecewise exponential, 501
  Poisson, 689
  Weibull, 31
Distribution-free test, 43
Diuretics, 269, 277
DMFT rates, 823
DMT model, 853
Dose-response effects, 241, 583
Drinking water, 823
Drug administration, mass (MDA), 853
Drug prescription, 863
Drug reactions, adverse, 863
Dysmenorrhea, 555

Early termination of clinical trials, 361, 369, 667, 753, 927
Effect size, 221
Efficacy of diagnostic tests, 411
Efficacy of treatment, 101, 657, 761
Efficiency of covariate adjustment, 31
Efficiency of monitoring systems, 517
EM algorithm, 91
Epidemiological methods, 53, 61, 71, 193, 197, 449, 469, 491, 501, 701
Epidemiology, 823, 843, 853, 863, 869, 961
  cancer, 449, 469, 881
  genetic, 629
  heart disease, 501
Error, measurement, 31, 647
Error rate, type I case-control study, 53
  clinical trials, 119, 773
  diagnostic tests, 147
  generalized Wilcoxon test, 483
  logrank test, 483, 577
  reliability studies, 441, 647
  time-dependent events, 689
  t-test, 577
Evaluation of combination preparations, 657
Evaluation of diagnostic tests, 411
Evaluation of treatment, 657
Excess ratio, 701
Exponential distribution, 501, 565
Exposure-covariate interaction, 193
Extrapyramidal reaction, 863

Facial pain, 137
Factorial designs, clinical trials, 773
Familial correlation, 629
Fischer's method for combining probabilities, 265, 381, 387
Fixed effects model, 341, 381
Fluoride, 823
Follow-up studies, 185, 599, 689, 785, 795

Gastro-intestinal bleeding, 269
Genetic epidemiology, 629
Genetic models, 629
Genetics, human, 629, 961
German–Austrian multicentre study (GAMS), 255
Graphical presentation of overviews, 341, 349
Greenwood's formula, 679
Group randomization, 43
Group sequential methods, 361, 369, 753, 927
Growth curve model, 185, 599
Growth standards, 185
Guillain–Barre syndrome, 795

Haemorrhage, gastrointestinal, 269
  intra-cranial, 315
Harmonic regression, 167
Hazards model, Cox proportional, 31, 501, 591, 773

Health insurance plan (HIP) study, 885
Health survey, 869
Healthy worker effect, 901
Heart disease, 217, 233, 255, 281, 295, 351, 501, 709
Heart rate, 159
Heterogeneity in controls, 221
Heterogeneity, study, 287, 329, 349, 351, 359, 395
Hodgkin's disease, 517
Homogeneity, test of marginal, 91
Hormones, 185
Human genetics, 629, 961
Human growth, 185
Hypothesis testing, 3, 101

Identifiability problem, 449, 469, 709
Imbalance in patient allocation, 119, 127, 241, 577
Incidence, cancer, 449, 469
Independence Bayes model, 805, 945
Independent samples *t*-test, 79
Index, mortality, 71
Indirect standardization, 61, 193, 449
Industrial cohort study, 901
Infancy–childhood–puberty model, 185
Infectious disease, 843
Inference, statistical, 101, 277, 369, 387, 745
Inheritance, 629
Interaction, exposure-covariate, 193
  qualitative, 329, 351, 359, 371, 387
  quantitative, 329, 359, 371, 387
  stratum-covariate, 221, 233, 371, 381, 773
  treatment-period, 911
Interim analysis in clinical trials, 361, 369, 753, 927, 939
International Cancer Research Data Bank (ICRDB), 11
International Society for Clinical Biostatistics (ISCB) Seventh International Meeting, Cardiff
  committees, 731
  papers, 733–874
  preface, 729
Interobserver variation, 411
Inter-study variation, 287, 329, 349, 351, 359, 395
Intraclass correlation, 43, 441, 647
Intracluster correlation, 491
Irreversibility of brain death, 535

Jacard coefficient, 137
Journals, statistics in medical, 3

Kaplan–Meier curve, 679
Kaunas–Rotterdam intervention study (KRIS), 501

Laboratory determinations, reference values, 147
Laboratory monitoring, 147, 425
Latent class model, 529(L), 530(L)
Lead-time bias, 885
Lead-time interval, 885
Length bias, 885
Lexis diagram, 469
Life support, 535
Life table, cause-deleted, 527(L)
Limits, discrimination, 147
Linear regression, 599
Linoleic acid, plasma, 599
Logistic regression model, 501, 583, 863
Logistic transformation, 43
Log-linear drift model, 449, 469
Log-linear model, 449, 469, 501, 555, 785
Logrank test, 119, 483, 565, 577, 773
Longitudinal data, 185, 599, 689, 785, 795
Loss function, 101
Loss table, 101

McNemar statistic, 53
Malaria, 853
Mantel–Haenszel statistic, 341, 491, 565, 701
Marginal homogeneity, test of, 91
Markov process, 795
Matched-pairs, 53
Maternity services, 613
Means, comparison of, 79
Measurement error, 31, 647
Medical journals, statistics in, 3
Medical records, 613
Meta-analysis, 11, 217–410, 565, 733
Metoclopramide, 863
Micro-organisms, susceptibility of, 91
Missing data in contingency tables, 91
Model, age–cohort, 449
  age–period, 449
  age–period–cohort, 449, 469, 709
  ARMA, 167
  Bayes, independence, 805, 945
  Box–Jenkins, 159
  competing risks, 785
  Cox proportional hazards, 31, 501, 591, 773
  cure rate, 483
  Dietz, Mollineaux and Thomas, 853
  fixed effects, 341, 381
  genetic, 629
  growth curve, 185, 599
  independence Bayes, 805, 945
  infancy–childhood–puberty, 185
  latent class, 529(L), 530(L)
  logistic regression, 501, 583, 863
  log-linear, 449, 469, 501, 555, 785
  log-linear drift, 449, 469
  moving average, 167, 425
  multiplicative for rates, 61
  multistate, 795

Model—*contd*
random effects, 241, 341, 359, 381, 403, 599
stochastic, 843
transient state, 795
Mojena's test, 137
Monitoring, data, 753
disease, 197
laboratory, 425
patient, 813
systems, rare event, 517
Monte Carlo simulation, 43, 53, 61, 71, 127, 483, 517, 577, 599, 657, 667, 689, 927
Mortality, 251, 709
cancer, 449, 469, 881
cause-deleted, 527(L)
cause-specific, 71, 233
occupational, 71, 901
Mortality index, 71
Mortality rates, 501, 527(L), 709
Mortality ratio, proportional, 71
Mortality ratio, standardized, 71, 193, 449, 701, 901
Moving average model, 167, 425
Multiple comparisons, 71, 591, 657
Multiplicative model for rates, 61
Multistate model, 795
Myocardinal infarction, 233, 255, 281, 295, 305, 315, 341, 351, 397, 529(L), 733

National Cancer Institute, 217
National Heart, Lung and Blood Institute, 217
Negative binomial distribution, 823
Neonatal nutrition, 599
Non-parametric tests, 43
Numerical taxonomy, 137
Nutrition, neonatal, 599

Observational study, 185, 599, 689, 785, 795
Observed minus expected method, 241, 265, 351
Obstetric records, 613
Occupational mortality, 71, 901
Odds ratio, 43, 53, 233, 255, 341, 491, 555, 565, 701
Odds ratio, variance of, 491
Ordinal scales, 79
Overview of clinical trials, 11, 217–410, 565, 733
graphical presentation, 341, 349

Pain, abdominal, 945
Pain, back, 657
Pain, facial, 137
Pain dysfunction syndrome, temperomandibular, 137
Patient selection, 113
Pedigree analysis, 629
Persantine–aspirin–reinfarction study (PARIS), 255
Piecewise exponential distribution, 501
Placebo effect, 113
Plasma exchange, 795
Poisson distribution, 689
Poisson process, 197
Pooling clinical trials, 11, 217–410, 565, 733
Postal questionnaires, 613
Power
case-control studies, 53
clinical trials, 119, 577, 773, 927
diagnostic test, 147
generalized Wilcoxon test, 483
logrank test, 483, 577
reliability studies, 441, 647
spectra, 159
time-dependent events, 689
t-test, 577
Pragmatic clinical trials, 101, 389
Preclinical phase, detectable, 885
Predictive value of diagnostic tests, 411
Preoperative tests, 813
Prescription, drug, 863
Presentation, graphical, 341, 349
Prevalence, disease, 961
Probabilities, combining, 265, 341, 381, 387
Probability, understanding of, 3, 535
Process, Markov, 795
Process, Poisson, 197
Prognostic factors, 31, 773
Proportional change, 113
Proportional hazards model, Cox, 31, 501, 591, 773
Proportional mortality ratio, 71
Proportions, combining, 565
Publications bias, 11, 221, 229, 295, 315, 327, 333, 361, 733
Pulmonary disease, 491

Qualitative interaction, 329, 351, 359, 371, 387
Quality control, internal, 425
Quangle, 425
Quantitative interaction, 329, 359, 371, 387
Questionnaire design, 613

Radiotherapy, 785
Random effects model, 241, 341, 359, 381, 403, 599
Randomization, 43, 119, 127, 229, 233, 241, 251
Randomization, group, 43
Randomization, replacement, 127
Randomized clinical trials—see clinical trials,
Rates, age standardized, 61, 449, 469
Rates, DMFT, 823
Rates, mortality, 501, 527(L)
Rates, multiplicative model, 61
Ratio, concordance, 961
discordance, 961

Ratio—*contd*
excess, 701
odds, 43, 53, 233, 255, 341, 491, 555, 565, 701
proportional mortality, 71
standardized mortality, 71, 193, 449, 701, 901
Receiver operating characteristic curve, 411
Records, obstetric, 613
Recurrence, cancer, 245, 251
Recurrent events, 689
Reference range, clinical chemistry, 147
Reference tests, 411
Register of clinical trials, 11, 327
Regression, Cox proportional hazards model, 31, 501, 591, 773
harmonic, 167
linear, 599
logistic, 501, 863
to the mean, 113, 727(L), 728(L)
Relative efficiency, 517
Relative risk, 193, 591, 689, 773
Reliability studies, 441, 647
Reliability, test-retest, 441, 647
Repeated measurements, 441, 599, 647, 911
Repeated significance tests, 753
Replacement randomization, 127
Resemblance matrix, 137
Review bias, diagnostic test, 411
Rhythm, circadian, 167
Rigoni–Stern, 877, 881
Risk factors, 255, 501, 629, 961
Risk model, competing, 785
Risk, relative, 193, 591, 689, 773
Risk score, 689
Robustness, *t*-test, 79
ROC curve, 411
Rubella, 843

Safety of Medicines, Committee on (CSM), 863
Sample size, case-control study, 53
clinical trials, 119, 577, 667
diagnostic test, 147
generalized Wilcoxon test, 483
logrank test, 483, 577
reliability studies, 441, 647
survival curve, 679
t-test, 577
Scales, ordinal, 79
Scan statistic, 197
Screening, 813, 885
Selection bias, 127, 251, 315, 389
Selection of patients, 113
Selection of studies for meta-analysis, 221, 229, 233, 241, 245, 265, 277, 295, 333, 403
Selection of treatment, 101, 287, 337, 359, 745
Sensitivities, comparison of, 147
Sensitivity analysis, 530(L)
Sensitivity of diagnostic tests, 147, 411
Sequential analysis, 361, 369, 753
Sequential clinical trials, group, 361, 369, 753
Serum bile acids, 147
Sets surveillance technique, 517
Shewhart chart, 425
Sickle cell disease, 689
SIDS, 159
Simulation, Monte Carlo, 43, 53, 61, 71, 127, 483, 517, 577, 599, 657, 667, 689, 927
Size of sample, see sample size
Space–time cluster, 197
Specificity of diagnostic tests, 147, 411
Spectra, power, 159
Split-plot structure, 911
Spontaneous abortion, 197
Square contingency tables, 91
Standard deviation, 3
Standard error, 3
Standardized mortality ratio, 71, 193, 449, 701, 901
Standardized rates, 61, 449, 469
Standardization, indirect, 61, 193, 449
Standards, growth, 185
Statistical inference, 101, 277, 369, 387, 745
Statistics in medical journals, 3
Stochastic curtailment, 667, 753
Stochastic model, 843
Stopping rules for clinical trials, 361, 369, 927
Stouffer's method for combining probabilities, 341
Stratification, 241
Stratum-covariate interaction, 221, 233, 371, 381, 773
Stroke, 233
Study heterogeneity, 287, 329, 349, 351, 359, 395
Subgroup analysis, 233, 241, 245, 277, 295, 361, 371, 379, 397
Sudden infant death syndrome (SIDS), 159
Suicide, 709
Surveillance system, 197, 517
Survey methodology, 869
Survey of meta-analysis, 733
Surveys, postal, 613
Survival analysis, 31, 119, 361, 483, 501, 527(L), 565, 583, 591, 667, 679, 773, 785, 795, 885, 927, 939
Survival distribution, Weibull, 31
Swedish longitudinal growth study, 185
Symmetry, compound, 911

Tamoxifen, 245, 287, 329, 333, 337, 371, 379
Taxonomy, numerical, 137
Teaching diagnosis, 805
Teaching medical statistics, 3
Teaching survey methodology, 869
Temperature, body, 167
Temperomandibular pain dysfunction syndrome, 137

Termination of clinical trials, 361, 369, 667, 753, 927
Test, diagnostic, 147, 411, 813
  logrank, 119
  marginal homogeneity, 91
  Mojena's, 137
  reference, 411
Test–retest reliability, 441, 647
Thoracic disorder, 805, 813
Three decision problem, 101
Three period crossover trial, 555
Time-dependent recurrent events, 689
Time series analysis, 159, 167
Titration, 583
Tolerance dose, 583
Tracking signal, Trigg's, 425
Transformation, logistic, 43
Transient state model, 795
Transmission, malaria, 853
Treatment, adverse effects, 745, 863
  allocation, 119, 127, 241, 577
  balance, 119, 127, 241, 577
  efficacy, 101, 657, 761
Treatment-period interaction, 911
Treatment selection, 101, 337, 359, 745
Trigg's tracking signal, 425
t-test, independent samples, 79, 577
  robustness of, 79
Twin studies, 961
Two-period crossover trial, 911

Utility, 745, 945

Vaccination, 843
Variance, analysis of, 441, 599, 647
Variance, attributable fraction, 701
Variance, odds ratio, 491
Variation, extra-binomial, 491
Variation in cancer rates, 449, 469
Variation, inter-observer, 411
Variation, inter-study, 287, 329, 349, 351, 359, 395
Vegetative state, 535
Verification bias, 411
Veterans Administration Lung Study Group, 31
Vinyl chloride monomer (VCM), 901
V-mask, 425

Waller–Duncan method, 591
Ward's hierarchical method, 137
Water, drinking, 823
Weibull distribution, 31
Wilcoxon test, generalized, 483
Workshop on Methodologic Issues in Overviews of Randomized Clinical Trials
  preface, 217
  proceedings, 217–410
  speakers and discussants, 219
  sponsors, 217

X-ray, chest, 813